OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results, Misses Estimates By $0.08 EPS

OraSure Technologies (NASDAQ:OSUR) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08), FiscalAI reports. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Management expects mid-year FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and the Colli‑Pee at‑home urine collection device, with revenue ramps anticipated in the second half of 2026.
• Q1 revenue was $27.9 million (above guidance midpoint) and non‑GAAP gross margin expanded to 43.4%, driven by insourcing production into its Pennsylvania facilities and improved operating efficiencies.
• OraSure finished Q1 with $177 million cash and zero debt while returning $20 million to shareholders via buybacks over the last four quarters, but operating cash flow was negative $14 million with management targeting break‑even cash flow in 2027.
• International progress includes initial orders to a nearshoring partner, planned follow‑on orders in H2, and expanded reach for Sickle SCAN via BioMedomics integration and national health program relationships.
• Operating expenses remain elevated—Q1 R&D was $13.7 million (launch preparation) and G&A rose due to severance and one‑time items—contributing to a GAAP operating loss of $23.3 million, though management expects R&D and G&A to normalize later in 2026.

OraSure Technologies Price Performance

NASDAQ:OSUR remained flat at $3.00 during mid-day trading on Wednesday. The company had a trading volume of 583,251 shares, compared to its average volume of 324,072. The company has a market capitalization of $215.91 million, a price-to-earnings ratio of -3.23 and a beta of 0.89. The firm’s 50 day moving average price is $3.05 and its 200 day moving average price is $2.76. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $3.82.

More OraSure Technologies News

Here are the key news stories impacting OraSure Technologies this week:

• Positive Sentiment: Q1 revenue slightly beat expectations: total revenue was about $27.9M, roughly $0.2M above consensus — showing demand resilience in the quarter. Revenue beat article
• Neutral Sentiment: Company issued its formal Q1 press release and held an earnings call/transcript that outlined operating challenges and strategic priorities (cost discipline, focus on point‑of‑need/home diagnostics and sample management). Investors can review the management commentary for color on execution and timing of any turnaround. Press release Earnings transcript
• Neutral Sentiment: Broker/summary coverage and company filings (TipRanks, MarketBeat) are available summarizing results and linking to the call for deeper review. TipRanks summary
• Negative Sentiment: EPS missed materially: non‑GAAP EPS was negative (about -$0.24), missing consensus by roughly $0.07–$0.08; profitability remains weak with a large negative net margin and negative return on equity — key reasons for investor concern. EPS miss article
• Negative Sentiment: Cautious Q2 guidance: revenue guidance was set at $27.0M–$30.0M versus a ~ $29.1M consensus, signaling conservative near‑term expectations; that guidance plus the EPS miss is likely exerting downward pressure on the stock. Guidance/press release
• Negative Sentiment: Higher trading volume than average accompanied the release, suggesting stronger investor reaction; combined with continued operating losses, the report increases short‑term downside risk until evidence of margin improvement appears. Market reaction summary

Insider Activity at OraSure Technologies

In related news, CEO Manner Carrie Eglinton acquired 32,300 shares of the stock in a transaction dated Friday, March 20th. The shares were acquired at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief executive officer owned 2,190,874 shares in the company, valued at approximately $6,419,260.82. The trade was a 1.50% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Kenneth J. Mcgrath acquired 32,300 shares of the stock in a transaction dated Friday, March 20th. The stock was bought at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the purchase, the chief financial officer owned 589,562 shares of the company’s stock, valued at $1,727,416.66. The trade was a 5.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 108,643 shares of company stock worth $321,407. Company insiders own 3.90% of the company’s stock.

Institutional Trading of OraSure Technologies

A number of hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in shares of OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after purchasing an additional 878,151 shares during the period. Geode Capital Management LLC raised its position in shares of OraSure Technologies by 6.4% during the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock valued at $5,611,000 after buying an additional 112,851 shares during the last quarter. Cannell Capital LLC lifted its stake in shares of OraSure Technologies by 33.7% in the second quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock valued at $5,595,000 after buying an additional 470,536 shares during the period. Kotler Kevin bought a new stake in shares of OraSure Technologies in the fourth quarter valued at about $4,359,000. Finally, Bridgeway Capital Management LLC grew its position in OraSure Technologies by 9.5% during the second quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock worth $5,371,000 after buying an additional 154,985 shares in the last quarter. 93.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, OraSure Technologies has an average rating of “Reduce” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.